title: Aspirin resistance after CABG.
abstract: BACKGROUND
  Temporary aspirin resistance can occur during the post-CABG period. If the factors causing resistance can be identified, the incidence of early graft occlusions can also be minimized.
  
  
  METHODS
  25 elective CABG cases were enrolled in the study. The platelet count, mean platelet volume, the C-reactive protein level, lipid profile, blood urea nitrogen (BUN), and creatinine levels were identified one day before the operation and on the 1st, 5th and 10th postoperative days. Optical aggregometry was used for the evaluation of aspirin response. The patients were divided into two groups: those with aspirin resistance and those with no aspirin resistance.
  
  
  RESULTS
  The rate of postoperative aspirin resistance was found to be 60 %. No significant difference was found when the preoperative and operative data of the two groups were compared. It was found that the rapid changes observed in the postoperative platelet counts and the C-reactive protein levels were similar.
  
  
  CONCLUSIONS
  Aspirin resistance is encountered during the early postoperative period in the majority of patients undergoing CABG. None of the factors studied were found to be causative for resistance formation. Further studies are required to clarify this entity.
authors.affiliation: Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Haydarpasa, 34420 Istanbul, Turkey. sanioglu@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Sanioglu
authors.forename: S
authors.initials: S
authors.lastname: Tetik
authors.forename: O
authors.initials: O
authors.lastname: Sokullu
authors.forename: H
authors.initials: H
authors.lastname: Deniz
authors.forename: N
authors.initials: N
authors.lastname: Aydemir
authors.forename: M
authors.initials: M
authors.lastname: Yilmaz
authors.forename: I Y
authors.initials: IY
authors.lastname: Arslan
authors.forename: F
authors.initials: F
authors.lastname: Bilgen
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D002097:C-Reactive Protein / Q000378:metabolism; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000097:blood / Q000601:surgery*; D003401:Creatine / Q000097:blood; D004351:Drug Resistance; D005260:Female; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011184:Postoperative Period; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008055:Lipids; D010975:Platelet Aggregation Inhibitors; D002097:C-Reactive Protein; D003401:Creatine; D001241:Aspirin